Complete ERNA Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
ERNA DCF Analysis
ERNA (Eterna Therapeutics Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $68.0K | $582.0K | $727.5K | $909.4K | $1.1M | $1.4M | $1.8M |
| Revenue Growth % | - | Infinity% | 755.9% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| EBIT | $-33.2M | $-21.1M | $-15.7M | $36.4K | $45.5K | $56.8K | $71.0K | $88.8K |
| EBIT Margin % | 0.0% | -31080.9% | -2693.1% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-24.9M | $-15.9M | $-11.8M | $27.3K | $34.1K | $42.6K | $53.3K | $66.6K |
| NOPAT Margin % | -Infinity% | -23310.7% | -2019.8% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $297.0K | $19.0K | $369.0K | $21.8K | $27.3K | $34.1K | $42.6K | $53.3K |
| Capex / Revenue % | Infinity% | 27.9% | 63.4% | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
| Depreciation | $497.0K | $1.1M | $1.6M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| D&A / Revenue % | Infinity% | 1651.5% | 281.4% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Change in NWC | $-9.1M | $-3.0M | $-3.6M | $7.3K | $9.1K | $11.4K | $14.2K | $17.8K |
| NWC Change / Revenue % | -Infinity% | -4413.2% | -620.6% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% |
| Unlevered FCF | $-15.7M | $-11.7M | $-6.9M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| UFCF % Chg. | - | 24.9% | 41.5% | Infinity% | NaN% | NaN% | NaN% | NaN% |
| FCF / Revenue % | -Infinity% | -17273.9% | -1181.2% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Discount Factor | - | - | - | 0.750 | 0.562 | 0.421 | 0.316 | 0.237 |
| Present Value of FCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| Sum of PV of UFCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.9% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.2% |
| Risk Free Rate | 4.37% |
| Market Risk Premium | 4.3% |
| Beta | 7.12 |
| Cost of Equity | 35.2% |
| Total Debt | $684.0K |
| Market Cap | $10.8M |
| Total Capital | $11.5M |
| Debt Weighting | 6.0% |
| Equity Weighting | 94.0% |
| WACC | 33.4% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $InfinityB |
| Terminal Value | $InfinityB |
| PV of Terminal Value | $InfinityB |
| Cumulative PV of UFCF | $InfinityB |
| Net Debt | $-1.0M |
| Equity Value | $InfinityB |
| Shares Outstanding | 13.6M |
| Implied Share Price | $InfinityB |
| Current Share Price | $0 |
| Implied Upside/(Downside) | +Infinity% |
Valuation Summary
$Infinity
Implied Price
$0.17
Current Price
+Infinity%
Upside/Downside
33.4%
WACC
ERNA Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 9 peer companies in Healthcare
P/E Ratio
$-0.87
-601.9%
Peer Median: 1.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 1.2x
P/S Ratio
$0.00
-97.9%
Peer Median: 0.4x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for ERNA's business model and current situation.
Multiple Comparison
| Multiple | ERNA Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.2x | 1.0x | 1.0x | -119.9% | Undervalued |
| EV/EBITDA | Infinityx | 1.2x | 1.2x | Infinity% | Overvalued |
| P/S Ratio | 20.2x | 0.4x | 1.2x | 4626.7% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.02B | 0.0x | 0.0x | 45.0x | |
| $0.02B | 0.0x | 0.0x | 3.0x | |
| $0.02B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 20.2x | |
| $0.01B | 0.0x | 0.0x | 240.2x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 1.0x | 1.2x | 0.2x | |
| $0.01B | 0.0x | 0.0x | 0.4x |